Overview
- Roche, which announced the deal Thursday, agreed to pay $750 million upfront with up to $300 million in milestone payments.
- The companies expect to close in the second half of 2026 after antitrust and other regulatory reviews, with PathAI set to join Roche Diagnostics.
- Roche plans to scale PathAI’s AISight image system to turn microscope slides into high‑resolution digital images and to automate review so labs can deliver results faster.
- The companies say combining PathAI’s AI tools with Roche’s oncology platforms could speed biomarker discovery, enable AI-driven companion tests, and support clinical trials.
- The acquisition builds on a partnership that began in 2021 and expanded in 2024 to develop AI algorithms for companion diagnostics.